Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.

OBJECTIVE: Data on anti-tumor necrosis factor (anti-TNF) treatment and suboptimal response (SOR) among patients with inflammatory bowel diseases (IBD) in Latin America (LATAM) are scarce. This study evaluated the incidence and indicators of SOR to anti-TNF therapy in patients with ulcerative colitis (UC) and Crohn's disease (CD) from Argentina, Colombia and Mexico. PATIENTS AND METHODS: We performed retrospective analysis of data from LATAM patients of the EXPLORE study (NCT03090139) including adult patients with IBD who initiated anti-TNF therapy between March 2010 to March 2015. The cumulative incidence of SOR to first-line anti-TNF therapy was assessed. A physician survey to assess barriers to anti-TNF therapies was also carried out. RESULTS: We included 185 IBD patients (UC/CD: 99/86) treated with first-line anti-TNF from Argentina (38 UC; 40 CD), Colombia (21 UC; 25 CD) and Mexico (40 UC; 21 CD). 36.4% of patients with UC and 46.5% of patients with CD experienced SOR to anti-TNF therapy during the median (interquartile range) observational period: 49.0 months (37.2-60.1) in UC, and 50.0 months (40.9-60.1) in CD. The most common indicator of SOR among patients was augmentation of non-biologic therapy (UC: 41.7%; CD: 35.0%). Affordability and late referral to IBD specialist care centers were the most common barriers to anti-TNF therapies. CONCLUSIONS: SOR to anti-TNF therapy was common in LATAM IBD patients, where augmentation with non-biologic therapy represented the most frequent indicator of SOR across indications. Our findings contribute to the current evidence on the unmet needs associated with anti-TNF in LATAM.

Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients.

AIM: To evaluate novel risk factors and biomarkers of cardiovascular disease in celiac disease (CD) patients compared with healthy controls. METHODS: Twenty adult patients with recent diagnosis of CD and 20 sex, age and body mass index-matched healthy controls were recruited during a period of 12 mo. Indicators of carbohydrate metabolism, hematological parameters and high sensitive C reactive protein were determined. Moreover, lipoprotein metabolism was also explored through evaluation of the lipid profile and the activity of cholesteryl ester transfer protein and lipoprotein associated phospholipase A2, which is also considered a specific marker of vascular inflammation. The protocol was approved by the Ethic Committee from School of Pharmacy and Biochemistry, University of Buenos Aires and from Buenos Aires Italian Hospital, Buenos Aires, Argentina. RESULTS: Regarding the indicators of insulin resistance, CD patients showed higher plasma insulin levels [7.2 (5.0-11.3) mU/L vs 4.6 (2.6-6.7) mU/L, P < 0.05], increased Homeostasis Model Assessment-Insulin Resistance [1.45 (1.04-2.24) vs 1.00 (0.51-1.45), P < 0.05] and lower Quantitative Sensitive Check index [0.33 (0.28-0.40) vs 0.42 (0.34-0.65), P < 0.05] indexes. Folic acid concentration [5.4 (4.4-7.9) ng/mL vs 12.2 (8.0-14.2) ng/mL, P < 0.01] resulted to be lower and High-sensitivity C reactive protein levels higher (4.21 ± 6.47 mg/L vs 0.98 ± 1.13 mg/L, P < 0.01) in the patient group. With respect to the lipoprotein profile, CD patients showed lower high density lipoprotein-cholesterol (HDL-C) (45 ± 15 mg/dL vs 57 ± 17 mg/dL, P < 0.05) and apo A-I (130 ± 31 mg/dL vs 155 ± 29 mg/dL, P < 0.05) levels, as well as higher total cholesterol/HDL-C [4.19 (3.11-5.00) vs 3.52 (2.84-4.08), P < 0.05] and apo B/apo A-I (0.75 ± 0.25 vs 0.55 ± 0.16, P < 0.05) ratios in comparison with control subjects. No statistically significant differences were detected in lipoprotein-associated lipid transfer protein and enzymes. CONCLUSION: The presence and interaction of the detected alterations in patients with CD, would constitute a risk factor for the development of atherosclerotic cardiovascular disease.

[Is the preparation with sodium phosphate purgative for bowel cleansing safe in low-risk patients?]. / Es segura la preparación con laxante de fosfato sódico para la limpieza colónica en pacientes de bajo riesgo?

UNLABELLED: The development of colonoscopy has increased the oral sodium phosphate (OSP) laxative use. OSP complications like hyperphosphatemia with acute and chronic kidney impairment with nephrocalcinosis have been reported. OBJECTIVE: To describe and analyze acute and one year after OSP complications in low risk well hydrated patients. METHODS: We performed a prospective study in 100 consecutive patients undergoing colonic cleansing with OSP for colonoscopy aged 35-74 year, ASA I-II. Exclusion criteria were congestive heart failure, chronic kidney disease, diabetes, liver cirrhosis, intestinal obstruction, decreased bowel motility, increased bowel permeability, hyperparathyroidism. Arterial pressure, hematocrit, serum osmolality, serum phosphate, ionic calcium, electrolytes (Na+, Cl-, K+), creatinine and urea were measured before and after OSP. The day before colonoscopy all the participants entered a 24 hr-period diet consisting in 4 litres of clear fluids and standard OSP dose (30 g at 17:00 and 30 gr at 22:00). Phosphatemia levels post OSP according to patient's weight (> or =, < or = 70 kg) and one year later kidney function were compared. RESULTS: Mean age was 58.9 +/- 8.4 years, 66% of patients were women and mean weight was 71 +/- 13 kg. Kidney function showed no significant difference between pre and post OSP, and after one year values. Hyperphosphatemia appeared in 87%. Hyperphosphatemia was higher in patients with low weight (5.8 mg/dl vs 5.3 mg/dl, P < 0.05). CONCLUSION: OSP complications were reduced through an adequate patient selection in order to avoid risk factors and an effective hydration. Phosphate overload was tolerated without symptoms. Considering high hyperphosphatemia incidence and its relation with weight, to adjust dose related to weight should be evaluated. There was no acute or a year later renal damage.

[Celiac disease: diagnosis prevalence in a community hospital]. / Enfermedad celíaca: prevalencia del diagnóstico en un hospital de comunidad.

INTRODUCTION: Celiac disease (CD) is a gluten-sensitive enteropathy characterized by a chronic injury of the small bowel, caused by gluten intolerance in genetically predisposed individuals. The different forms of presentation of CD resemble more a multisystem disorder than a primary gastrointestinal disease and it is frequently underdiagnosed. OBJECTIVE: To determine the prevalence of CD diagnosis in the population of affiliates to the HMO of the Hospital Italiano de Buenos Aires. METHODS: This is a cross sectional study, using secondary databases of diagnosis and laboratory from the electronic medical record (EMR) in a HMO population between 1998 and 2006. The criteria used to define a case was based on a diagnosis of CD in the EMR and/or a IgA antitransglutaminase antibodies value >15 AU/mL. RESULTS: According to these criteria, 283 patients with CD were identified in 128,748 individuals of the HMO. The prevalence of CD was 0.22%. The mean age of this group was of 42.3 years, and 80.2% of them were female. CONCLUSIONS: In a primary care HMO setting, using secondary databases from EMR we found 1 case of celiac disease every 470 affiliates, giving a prevalence of 0.22%. The rate between serological prevalence of CD and clinical diagnosis carried out in our center was near 3.3 to 1. Although this level of diagnosis could be considered relatively high, an important proportion of patients are left without diagnosis, considering the local estimated prevalence reported using serological tests. An increased level of awareness and clinical suspicion is needed at the primary care level.

Evaluación de pacientes con enfermedad de Crohn mediante RM con enteroclisis y ecografía Doppler / Doppler ultrasound and MR enteroclysis imaging of Crohn's disease

Objetivo: presentar nuestra experiencia en pacientes con enfermedad de Crohn del intestino delgado evaluados con ecografía Doppler (ED) y resonancia magnética con enteroclisis (RM). Material y métodos: se evaluaron 12 pacientes mediante ED y RM con contraste negativo (bario y metilcelulosa) y gadolinio. Se analizó la presencia de flujo en ED y tinción en la pared de las asas en RM, espesor parietal y complicaciones. Resultados: Todos los pacientes mostraron tinción de la pared por RM y en once flujo por ED. La correlación entre ambos métodos fue total en 10 pacientes. La RM mostró en 10 pacientes áreas de estenosis, mientras que la ecografía en 5 pacientes. Ambos métodos mostraron engrosamiento parietal, y en igual porcentaje fístulas y abscesos. Conclusión: Ambos métodos permiten identificar y cuantificar alteraciones en el intestino delgado en pacientes con enfermedad de Crohn, pudiendo ser útiles en la evaluación y seguimiento de estos pacientes

Evaluación de pacientes con enfermedad de Crohn mediante RM con enteroclisis y ecografía Doppler / Doppler ultrasound and MR enteroclysis imaging of Crohns disease

Objetivo: presentar nuestra experiencia en pacientes con enfermedad de Crohn del intestino delgado evaluados con ecografía Doppler (ED) y resonancia magnética con enteroclisis (RM). Material y métodos: se evaluaron 12 pacientes mediante ED y RM con contraste negativo (bario y metilcelulosa) y gadolinio. Se analizó la presencia de flujo en ED y tinción en la pared de las asas en RM, espesor parietal y complicaciones. Resultados: Todos los pacientes mostraron tinción de la pared por RM y en once flujo por ED. La correlación entre ambos métodos fue total en 10 pacientes. La RM mostró en 10 pacientes áreas de estenosis, mientras que la ecografía en 5 pacientes. Ambos métodos mostraron engrosamiento parietal, y en igual porcentaje fístulas y abscesos. Conclusión: Ambos métodos permiten identificar y cuantificar alteraciones en el intestino delgado en pacientes con enfermedad de Crohn, pudiendo ser útiles en la evaluación y seguimiento de estos pacientes (AU)